Research On PI3Ks and BTK Inhibitors market drivers of M&A in 2013-2016 - 2 views
-
Matilde Fernandes on 15 Jan 14Unmet needs in hematologic malignancies calls for companies focusing on PI3Ks and BTK inhibitors to offer better treatment options. Around USD 10 bn has already been invested in licensing and acquisition of PI3K and other kinase inhibitors since the last five years. Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell. Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential.